Fortrea Holdings Inc. (FTRE) Fair Value 2026

FTRE · Services-Medical Laboratories ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.5 /10

32 fundamental signals · 11 models active

Value Trap Risk

LOW (27/100)

Quick Summary — As of 2026-07-15, Fortrea Holdings Inc. (FTRE) trades at $17.91, approximately 268% above CirclFi’s Bayesian DCF fair value of $4.87. QOC: 5.5/10. Value Trap Risk: 27/100 (LOW). 11/13 models active.

Key Facts

Ticker
FTRE
Price
$17.91
Quality Score
5.5/10
Value Trap Risk
27/100
Models Active
11/13
Last Updated
Strength: Earnings Power Value suggests +72.5% upside with 54% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is Fortrea Holdings Inc. (FTRE) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Fortrea Holdings Inc. (FTRE) appears fairly valued as of : the median of 11 independent fair value estimates is $19.56, within 9.2% of the current price of $17.91. Estimates range from $1.71 to $38.26. FTRE scores 5.5/10 on fundamental quality and 27/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Fortrea Holdings Inc. Stock in 2026? →

Valuation Matrix

11 Intrinsic Value Models vs. Current Price ($17.91)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
 $4.87 -72.8%
Earnings Power Value
High Conviction
 $30.90 +72.5%
CUCE Ensemble
Low Conviction
 $19.56 +9.2%
First Chicago
Medium Conviction
 $1.71 -90.4%

Unlock the Full Matrix

Access 7 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is Fortrea Holdings Inc. (FTRE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Fortrea Holdings Inc.'s intrinsic value is estimated at $19.22, suggesting a +7.3% average upside from the current price of $17.91. While 8 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: Regime Cross targets $38.26 (+113.6%), versus First Chicago at $1.71 (-90.4%). This +204.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About FTRE?

11 of 13 models are currently active for FTRE. Of these, 8 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates FTRE's intrinsic value at $4.87, implying -72.8% downside from the current price. See which stocks rank higher →

How Does FTRE Rank in Services-Medical Laboratories?

Among 24 Services-Medical Laboratories stocks, FTRE ranks #18 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.

Fortrea Holdings Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is FTRE a Value Trap?

CirclFi's Value Trap algorithm assigns FTRE a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Fortrea Holdings Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Fortrea Holdings Inc. is rated at 5.5/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

The gap between the most bullish and bearish model spans +204.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every FTRE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across FTRE's 11 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Fortrea Holdings Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Services-Medical Laboratories Stocks Should You Also Analyze?

8 related Services-Medical Laboratories stocks with 13-model coverage

CSTLCastle Biosciences, Inc.QOC 9.2VCYTVeracyte, Inc.QOC 8.8DGXQuest Diagnostics IncorporatedQOC 8.3CDNACareDx, Inc.QOC 7.8FLGTFulgent Genetics, Inc.QOC 7.7LHLabcorp Holdings Inc.QOC 7.6RDNTRadNet, Inc.QOC 7.1XGNExagen Inc.QOC 7.0

Read investment analysis: CSTL · VCYT · DGX · CDNA · FLGT

Frequently Asked Questions About Fortrea Holdings Inc.

What is Fortrea Holdings Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Fortrea Holdings Inc. (FTRE) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $4.87. The Quality of Company score is 5.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is FTRE overvalued or undervalued right now?

At $17.91, 8 of 11 active models suggest FTRE may be undervalued, while 3 indicate potential overvaluation. The median of all 11 fair value estimates is $19.56, within 9.2% of the current price of $17.91 — a consensus view that FTRE is fairly valued. The assessment depends on which methodology best fits Fortrea Holdings Inc.'s business model in Services-Medical Laboratories.

What does a Quality of Company score of 5.5 mean for FTRE?

Fortrea Holdings Inc.'s QOC of 5.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on FTRE?

CirclFi analyzes FTRE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Is FTRE a value trap in 2026?

Fortrea Holdings Inc.'s Value Trap score is 27/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Fortrea Holdings Inc. (FTRE) has a median fair value of $19.56 — within 9.2% of the current price of $17.91 — as of 2026-07-15.” Source: circlfi.com/stock/FTRE/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on FTRE.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access